Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 28 of 28 results for cabozantinib

  1. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    24 March 2022
    View recommendations

    Sections for TA780

  2. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

    In development [GID-TA11587] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  4. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development [GID-TA11438] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued [GID-TA10830]

    Technology appraisal guidance
    Discontinued

  6. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals

  7. Past appeals and decisions

    emtansine (after trastuzumab & taxane) 13 October 2014 TA928 Cabozantinib for previously treated advanced differentiated thyroid cancer...

  8. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

      Status ...

    Health technology evaluations
    Topic selection

  9. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    In development [GID-TA11163] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued [GID-TA11204]

    Technology appraisal guidance
    Discontinued

  11. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    Evidence-based recommendations on selpercatinib (Retsevmo) for previously treated RET fusion-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    12 January 2022
    View recommendations

    Sections for TA760

  12. Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

    This guidance has been updated and replaced by NICE technology appraisal guidance 849.

    Technology appraisal guidance
    Published
    24 May 2019

  13. Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

    In development [GID-TA11433] Expected publication date: TBC

    Technology appraisal guidance
    In development